Because of HSF1’s role in promoting HSP70 and HSP90 refolding chaperone activity, inhibiting HSF1 would likely shift the preference of HSP70 and HSP90 towards CHIP and substrate degradation, thus providing a promising cancer treatment strategy. Here, STUB1 is linked to cancer.